Grifols (NASDAQ:GRFS) (NASDAQ: GRFS) is a global healthcare company specializing in plasma-derived medicines and hospital supplies. Founded in Barcelona in 1940 by Dr. José Antonio Grifols Lucas, the company has grown from a regional pharmaceutical laboratory into one of the world’s leading producers of therapeutic proteins. Over the decades, Grifols has expanded its capabilities through strategic acquisitions and investments in research and development, establishing a robust pipeline of plasma-based treatments used to address a range of rare and chronic conditions.
The company’s core business centers on plasma collection and fractionation, producing critical products such as immunoglobulins, albumin, and coagulation factors. These therapies play an essential role in treating patients with immune deficiencies, hemophilia, and other bleeding disorders. In addition to its bioscience division, Grifols operates a diagnostics segment that offers automated systems and reagents for blood typing, infectious disease screening, and molecular diagnostics. The hospital division provides intravenous medicines, infusion pumps, and medical devices aimed at improving patient care in acute and chronic settings.
With operations spanning more than 100 countries, Grifols maintains a comprehensive network of plasma donation centers and manufacturing facilities across the United States, Europe, and Latin America. This global footprint supports the company’s commitment to ensuring a reliable supply of life-saving therapies while adhering to stringent quality and regulatory standards. Under the leadership of President and Chief Executive Officer Víctor Grifols Roura and a seasoned management team, the firm continues to invest in innovation, digital transformation, and sustainability initiatives to meet evolving healthcare needs. Headquartered in Barcelona, Grifols remains dedicated to advancing plasma science and improving patient outcomes worldwide.
